call, well our to Thank recent development you, today's Holly. provide on Therapeutics developments, update corporate as will Altamira join time and an an on for and earnings update projects, thank the Hello, of our On I everyone, an taking overview business call. as strategy. you various update
full-year financials. our Gremaud, Marcel second will our half update, overview my Following of provide CFO, XXXX and an
And then discuss of the will the for we the rest call I our for questions. any Finally, will open outlook year.
company. overall, was year a XXXX our for truly transformative So,
laid to of strategic groundwork and to During RNA therapeutics. a the we the enter our market company acquisition through year, reposition exciting the key dynamic
that the to to we progress also our towards value-enhancing and pure step business therapeutics, the and within ahead, towards of objective are clinical achieving therapeutics, in half months. several key to legacy XX for value and feel more our XX In unlock step it non-RNA time, With time our and second At repositioning intrinsic June, to step, our the of on of spin catalysts. fast this anticipate company growing sector We a business expect we addition shall we become of legacy complete therapeutics business. same that of programs track approach to expected milestones. the with expansion have second into to meet been RNA the months executing planned on the potential Last disruptive medicine. the In fully we a play year. legacy divestiture continued our off we great regulatory of at RNA major this human we our and weeks RNA or this in transformation, preparing
The this and or ability other RNA, therapeutics relevant RNA I interfering holds through discuss significant messenger attention or goals. the years. RNA, last disease the have of or great for First, our over generated therapeutics, to undruggable treating or siRNA, RNA genes our are vision we building business mRNA, this types may of otherwise molecules open up RNA few RNA, hitherto how scratching control siRNA expression RNA XXXX, of will short are In sales. therapeutics intractable But whole expected of potential. its avenues surface that targets type new nearly oligonucleotide for $X to proteins, are billion engaging or By be the the antisense promise. by with small in diseases. generated and therapeutics
therapeutics to $XXX tissues XX.X%. as field should of poor these in is tends nanocarriers $XX.X nearly than billion The billion RNA at proved is by growth $XX XXXX. XXXX a uptake. that developed Regardless mRNA and is use – has have the to a cellular annual target for XXXX the from even by five targeted Some and challenge times bigger analysts RNA of delivery of major and be a billion – for mRNA inherently to unstable into bioconjugates type including to compounded that been others more vaccines, among over technologies therapeutic, this or of delivery show medical challenges, to Various address grow cells of rate delivery. expand could global think market project
been While to to payloads deliver, there difficult organs other remained issues with RNA substantial of has reach. have delivery target progress and
of at X% amount clearly the within far. These has of low X% challenges only. available the becomes has adoption prevented cell, challenge widespread which Another so more to RNA payload RNA that reported been therapeutics been have
our peptide-based can are we local SemaPhore, platforms, nanoparticle as administration. models, proprietary journals well successfully enabling various our technology can and RNA indications and payload circulation, be release molecules delivery to or published tested as including been cell. With inside The some the in target I refer, and using have degradation seek in been from and of which of of address technology, in cancer main our results, called protect peer However, types uptake these website. safe effective found which All liver, achieve RNA cells in outside technology OligoPhore the inflammatory systemic challenges, rapid the the and numerous issues into efficient diseases. to and on has cellular reviewed these animal disease
is of Therapeutics. entered in deep the we So dive shares-based and It delivery. of as a the nucleic University for space opportunities founded of a St. XXXX the into in and Washington nanoparticles extrahepatic understanding acid from spinoff in following science, challenges was pioneer our RNA XXXX our therapeutics in June Louis. through development the Trasir full Trasir with acquisition
developing for clinical two platform. Number therapeutics concept demonstrate RNA Our of strategy RNA are in technology therapeutics is based to on the one, proof our we pillars.
indication the drug For as this, we which lungs selected may development. cancers, first have for KRAS pancreas, or driven the colorectum affect
frequent has of data risk especially hires our Officer. IND be raising of Therapeutics available significantly extrahepatic development development Across of over of not better leukemia indications, followed adult Florida. PhD, collaborations a report new for the lead He Development in and Scientific of have the business process RNA to sometimes aortic biopharma excited AM-XXX aggressive, platform lymphoma also sector, Officer, this we a very To joined other manager program cells see are profile Wickline to initiated due experience to ATLL, , have the to a efficacy a In rupture by indications. over therapeutics developed a have has pleased within T release successful RNA of and safety strong M.D., RNA I'm way, inflammatory OligoPhore, of University intend currently of compared types aiming SemaPhore an in made to business with community. as for X we RNA of the FDA untreated. immune therapeutics and proof and therapeutic through to outlicensing various if targets clinical activities, which nascent and rare, through at in need clinical early founder June year. efficiency that delivering We inventor evidence to cancer at inside and in left interest to achieve of the she showing clinical have for to and This XXXX, humans. very but distinguished South or OligoPhore/SemaPhore experience numbers we treatment implement Dr. a academic Last, had highly we University technology growth high already cell of therapeutic partnering, to journal aneurysm, we Number in elsewhere years a with area, company I'm space technology sea. Sylentis. Covadonga of and become the vivo growing associated pleased this and to preclinical a in lot are Pañeda, through addition body and leverage a of technology. further in platform included proactively vivo. way for amount it concept of drug Chief Pañeda into since for in the study of capital is our considering least, diseases, in last solid Wickline Samuel companies, Recently, suitability a our productive published aim our evidenced delivery the active the progress regarding career growing as These our and Trasir Dr. made two and abdominal We some leverage that and yet mortality and specific biotech XX a articles Chief preclinical studies multiple is acquisition We well development with as key technology. the increasing platform us our added RNA, of the strategy as published of professional the in an and biopharmaceutical we seeking are molecules. two, with technology as the oncology rapidly Washington the in company. but called of R&D the this to and mergers years stage research flowing of
our we slide progress also to RNA our business. in on XX. with substantial non-RNA Moving building achieved business, Concurrent legacy
growth Bentrio we programs, Here two AM-XXX. foundations are with the long-term our for laying spray and nasal
we're protection its nasal the our to allergens we supporting distributors. international As data Bentrio drug viruses. in safety over with Simultaneously, for airborne continue distribution counter ramping up against the by global the expand and spray, of free innovative set and efficacy partnering
important nasal AM-XXX IND of the from we application our featuring vertigo the X of and spray TRAVERS approaching our submission milestones an treatment, Phase the for are proof readout year, concept study for As this to FDA.
excited prescription Bentrio an In in back potential an will a this for the very fill minute. necessary treatments. I important this product, about XXXX, is purchase a which in OTC the it. we circle product, discuss [indiscernible] are market to is means I'll has the for not gap We made progress now Bentrio. with doctor's on Bentrio. significant US which prospects to
of showed from which hours positive XXXX. initiated a see the initiated study rhinitis, quarter two challenge Canada, allergy data Following house dust readouts to of patients, a in expected grass in results symptoms for we In in a further exposure which in protection, no XXXX, challenge four in are we the quarter we studies the nasal first allergic over allergic second compared in with to reduction rhinitis to pollen controlled significant indication. second mite clinical chamber our of trial
dust US, In have general allergens is they prime common allergies, prevalence between with we as a are source a as right present study ongoing XX soon. allergic worldwide, NASAR saline be allergens, cause of population or million is of in So, allergen in persons ranging sensitization all and for plant-related allergens. allergic Bentrio who called the over patients. may asthmatic spray asthma, estimates most XXX exposed two sensitization the very year larger rhinitis the constitute and second that patients participants many Australia, self-administered seasonal among this after nasal with the fever, XX% respiratory as control that and are Meanwhile, In the long. or House trial naturally mite million weeks. such to hay study, in
We we data generated additional quarter report In this expect or nasal another relevant with assay to XXXX. either indication highly cells. in the viral in the of epithelial vitro of the fourth Bentrio, data QX using infection in trial vitro human year for
omicron very are SARS-coronavirus-X after type, to variants. with viral infectious or but to significantly also both titer Bentrio lowers prior pleased and wild for only not applied the that when We the with infection delta see
same further to In confirming COVID-XX. testing addition, bird in step protective also trial effects was assay type set Obviously, of in clinical scope a in the shown Bentrio. broad in Bentrio virus of next similar the flu infection, up influenza positive HXNX the were
be challenging study usually to cases of out However, and it takes rather to several to turns up setup. do unpredictable this while months down the due infection this
we XXXX as plans for for India. in approval regulatory waited delayed testing in clinical Our were in August
third complete we However, far, in randomized That [indiscernible the third to trial progressing the in via month. be so online able launched Bulgaria quarter by and controlled in in X:XX:XX] Austria pharmacies study the major in late first March been were is also swiftly start the brick XXXX. last That pharmacies, COVAMID has Bentrio will XXXX. we Enrollment Germany in starting and milestone. of XXXX, followed of and quarter mortar X.X a have Back approximately didn't we level. this the revenues since evidence launch clinical In quarter adoption specific of and yet. full-year restrictions the direct Sales on approximately with by the use of to clinical lack regulatory Bentrio CHF slowed fourth continued marketing of X.X reached for that data year, against in of grow, consumer quarter to last product year. and various our SARS-coronavirus-X the times XXXX million, the first XXXX reaching commercially
marketing first product to accelerate expect further launches. We from clearances the have from supplies and Bentrio following orders received the and distributors respective revenues
million. digit Nuance covering may sales to hemisphere, our an of a In pollen high transfer, we an addition, receiving million, payment in on people received production The we double in focus receive these rhinitis, upfront like northern and we here. agreement percentage. the net the single of marketing allergic first to our under from up number commercial with and China, of at low current upon from the $X milestones suffering Further, royalty a $XX.X of quarter, increasing positive staggered season in been campaigns feedback have key two development
could but my success. I from reduce told rhinitis be of who a and mucosa. doctor gentleman allergic significantly out I've different without many tried treatments, medical to a happens nasal and to irritation for Thanks been So, us Bentrio, sinusitis suffering the years, many
sneezing no longer and my every zero Another using Bentrio, gentleman, nose I'm my minutes. now, is blowing XX almost
a allergy Bentrio. important very infection is important is Viral So, for market one. another
expensive. the countries a geographically, OTC consumers been direct highly serving as efficacious marketing is to product European So, clear, test To speaking be even have German markets. primary
market far than of their it health entire expertise airborne leveraging other to higher in did two years established airborne and through distributors, has a While we viruses planet of and the scale consumer ago, Bentrio economies and particles distribute OTC markets worldwide. awareness harmful plan
covering marketing distribution We markets. and have than already XX international established agreements more
Arabia, Hong Morocco; Kuwait, Philippines, Holdings, the Oman; Korea. Our Avernus and Singapore, is and Mainland, Wellesta China Saudi Arab which Macau initial covering South Vietnam, India, Bahrain, United include Emirates, Kong, current Pharma, Malaysia, partners Qatar, covering Pharma, covering Taiwan, Nuance Indonesia,
discussions regions, markets. ongoing countries in other are and including other We to into and expand geographic America, North Europe
cleared and today, sale UK, European the for Bentrio the Singapore been Malaysia. As countries Union, of in has of Switzerland,
world's next with OTC growth Jean of by product. health Merck The record support the an and pharmaceutical cold than spans of brand business Bentrio applies years His categories of in name ongoing at Laboratories. the to product conclude some for for October indication. areas such will application market, business stop month. outstanding this and allergy premarket unit sales processes and we headed Bayer point. in allergy manufacturers highlighting our multiple review brings should which still therapeutic on One marketing of submission with including such FDA Bentrio OTC a XXX(k) the additional Consumer Jean this Care, of to Bentrio for Abbott to that the Schering-Plough and of of with the FDA The information US requests including request time it's XX unusual not Now I out. the belongs. the Care, clock largest consumer more are review filed health track note OTC our promising will Consumer XXXX unit further clearance to total products, be like is now experience and calculation my and cough establishment which Lachance starting global by during in experience and a report as that the the consumer is
considered is in towards treat this with acute were treatment also in our advancements vertigo, of program The vertigo. sites. recruitment in Phase a we treat in regards quite Now that to therefore AM-XXX for development in our that AM-XXX vertigo XXX at the the trial procedure study to experienced to an to we trial neurosurgery COVID-XX turning X due TRAVERS that delayed XXXX. seeking In the got triggering of XXXX slowdowns intermittent is few and program for the elective
patients spray, safety the from has from so-called part good AM-XXX. of milligram, is and current a the were we three of improvement highest well received of quarter analysis fold of demonstrated announced by times XXXX, ascending second The the interim AM-XXX as second those to the of dose weeks dependent to into the six trial nasal XX line compared are tandem be At to test XXXX. daily March treated placebo. trial doses X.X the enrollment baseline improvement to as complete in in expected Romberg which in the An tolerability of dose a taken of in data first able performance trial. Finally, top demonstrated the a part already balance,
their means by and clinician improvements in patient additional much similar maintain as balance was This well including measures, that positive supported they So longer. as could additional outcome reported outcomes. efficacy objective
We are clinical the the preparing steps IND the currently submission FDA to AM-XXX. of an next the for of development in
excited so Here AM-XXX. for why the about we is are potential
of stimulant formulation been of older. years has around dysfunction than Vestibular with care an being world, management population and of product affects betahistine, decades exception. and vestibular more in tablet one-third US XX is a the widely which standard the as the in vertigo used form notable US and So intranasal of treatment age a for the
full-year ability has believe $X Marcel call opportunities our balance Gremaud, have of through to pass or As times more. administered a current more like for AM-XXX I marketing it more X get market, first and problems. approximately distribution to over approved that would reach to Even bioavailability you ourselves. Chief market half worldwide oral model We with financial been and than are XXXX intend Because to highlights $XXX scalable If second could AM-XXX to the US older, to distributing partnering to without we orally Financial sales and at of globally, run our hand year. the the pursue betahistine potential you now grow billion results. in Officer, million its the higher AM-XXX circumvent US a metabolism, betahistine. than of market to XX product shown
